Gateway Investment Advisers LLC trimmed its position in shares of Danaher Co. (NYSE:DHR) by 10.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 32,305 shares of the conglomerate’s stock after selling 3,746 shares during the quarter. Gateway Investment Advisers LLC’s holdings in Danaher were worth $2,999,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds also recently made changes to their positions in the company. ETRADE Capital Management LLC lifted its holdings in Danaher by 5.1% in the second quarter. ETRADE Capital Management LLC now owns 19,075 shares of the conglomerate’s stock valued at $1,610,000 after buying an additional 917 shares during the period. Roundview Capital LLC lifted its holdings in Danaher by 2.0% in the second quarter. Roundview Capital LLC now owns 25,674 shares of the conglomerate’s stock valued at $2,167,000 after buying an additional 502 shares during the period. Honeywell International Inc. lifted its holdings in Danaher by 113.4% in the third quarter. Honeywell International Inc. now owns 640,100 shares of the conglomerate’s stock valued at $54,908,000 after buying an additional 340,100 shares during the period. Veritable L.P. lifted its holdings in Danaher by 28.2% in the second quarter. Veritable L.P. now owns 40,486 shares of the conglomerate’s stock valued at $3,417,000 after buying an additional 8,912 shares during the period. Finally, Wealthfront Inc. raised its holdings in Danaher by 10.2% in the second quarter. Wealthfront Inc. now owns 14,574 shares of the conglomerate’s stock worth $1,230,000 after purchasing an additional 1,348 shares during the period. Institutional investors own 75.88% of the company’s stock.
In related news, SVP Angela S. Lalor sold 42,988 shares of Danaher stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $102.29, for a total transaction of $4,397,242.52. Following the sale, the senior vice president now directly owns 82,008 shares of the company’s stock, valued at approximately $8,388,598.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Daniel L. Comas sold 62,989 shares of Danaher stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $101.96, for a total transaction of $6,422,358.44. Following the sale, the chief financial officer now directly owns 227,805 shares in the company, valued at $23,226,997.80. The disclosure for this sale can be found here. Insiders have sold a total of 274,913 shares of company stock worth $27,729,293 over the last ninety days. 12.20% of the stock is currently owned by insiders.
Shares of Danaher Co. (DHR) traded up $1.12 during trading on Wednesday, reaching $96.10. 1,468,347 shares of the company’s stock traded hands, compared to its average volume of 2,930,000. The company has a quick ratio of 1.05, a current ratio of 1.43 and a debt-to-equity ratio of 0.39. Danaher Co. has a twelve month low of $78.97 and a twelve month high of $104.82. The firm has a market cap of $66,850.00, a PE ratio of 27.46, a price-to-earnings-growth ratio of 2.01 and a beta of 1.04.
Danaher (NYSE:DHR) last released its earnings results on Tuesday, January 30th. The conglomerate reported $1.19 EPS for the quarter, beating the consensus estimate of $1.16 by $0.03. Danaher had a net margin of 13.60% and a return on equity of 11.36%. The firm had revenue of $5.09 billion for the quarter, compared to analyst estimates of $4.97 billion. During the same period last year, the firm earned $1.05 EPS. The business’s quarterly revenue was up 10.9% compared to the same quarter last year. equities analysts forecast that Danaher Co. will post 4.37 EPS for the current year.
The business also recently declared a quarterly dividend, which was paid on Friday, January 26th. Investors of record on Friday, December 29th were issued a dividend of $0.14 per share. This represents a $0.56 annualized dividend and a dividend yield of 0.58%. The ex-dividend date of this dividend was Thursday, December 28th. Danaher’s dividend payout ratio (DPR) is presently 16.00%.
DHR has been the topic of several analyst reports. Robert W. Baird reiterated a “buy” rating and issued a $99.00 target price on shares of Danaher in a report on Friday, December 15th. Citigroup increased their price objective on shares of Danaher to $107.00 and gave the stock a “buy” rating in a research report on Friday, December 15th. Cowen reissued a “buy” rating and set a $110.00 price objective on shares of Danaher in a research report on Tuesday, January 30th. UBS Group initiated coverage on shares of Danaher in a research report on Monday, January 22nd. They issued a “buy” rating and a $99.97 target price for the company. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $110.00 target price on shares of Danaher in a research report on Friday, January 19th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and an average target price of $100.13.
TRADEMARK VIOLATION WARNING: This piece of content was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/14/gateway-investment-advisers-llc-lowers-holdings-in-danaher-co-dhr.html.
Danaher Company Profile
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.